Gossamer Bio, Inc.
Close on Oct 19, 2026
- Market cap
- $2.77B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 4, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 27, 2026 | After market close | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 18, 2026 | Before market open | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 17, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 5, 2025 | After market close | $13.29M | $-0.21 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 5, 2025 | After market close | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 15, 2025 | After market close | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 13, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | After market close | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 12, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 5, 2024 | Before market open | – | – | – |
Press releases
Announcements Gossamer Bio filed with the SEC
Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Gossamer Bio Announces 1-for-80 Reverse Stock Split
Other events · EX-99.1 to Form 8-K
Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval
Material agreement · Unregistered share sale · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update
Material agreement · Agreement terminated · Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants
Regulation FD disclosure · EX-99.1 to Form 8-K
Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes
Regulation FD disclosure · EX-99.1 to Form 8-K
Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes
Material agreement · Agreement terminated · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Gossamer Bio Announces First Quarter 2026 Financial Results and Provides Business Update
Material agreement · Results of operations · Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Gossamer Bio, Inc. Launches Exchange Offer and Consent Solicitation Intended to Eliminate Over $120 Million of Debt with Existing Noteholder Support
Material agreement · Results of operations · Executive or director change · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Phase 3 PROSERA Topline Results February 2026
Other events · EX-99.1 to Form 8-K
Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study
Results of operations · EX-99.1 to Form 8-K
Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications
Material agreement · Agreement terminated · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Gossamer Bio Announces Second Quarter 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Gossamer Bio Announces $212 Million Private Placement Financing
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Interim TORREY OLE Update and PROSERA Phase 3 Design July 2023
Other events · EX-99.1 to Form 8-K
Gossamer Bio Announces First Quarter 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K